Global pharmaceutical industry saw a 0.3% decrease in 3D printing-related patent application in Q3 2022, compared to the previous quarter. The total number of 3D printing-related grants dropped by 7% in Q3 2022, according to GlobalData’s Patent Analytics.
Notably, 336 3D-printing-related patent applications were filed in the pharmaceutical sector in Q3 2022 compared to 337 in prior quarter.
15% of patenting activity came from the top five largest companies
Arkema has filed the most patents related to 3D printing in the pharmaceutical industry operations sector and technologies sector during Q3 2022, according to an analysis of patenting activity. The quarter saw Arkema file 23 3D printing-related patents, up from 18 in the prior quarter. It was followed by Johnson & Johnson with 10 3D printing patent filings, Jabil (7 filings), and 3D Systems (6 filings) in Q3 2022.
The US accounted for 26% of all patent filings.
In Q3 2022, the US accounted for 26% of 3D printing-related patent filings. China (20%) followed by South Korea (10%). The US accounted for 1% less than the 27% it held in Q2 2022.